Related coverage linked through entity extraction aliases.
Jun 19, 2026
AstraZeneca is advancing its oral GLP-1 drug into Phase III trials while defending dapagliflozin patents in Australia. The company obtained an Australian court injunction against a generic competitor and has partnered with Evinova to use AI for clinical trials. India could be a future market for the oral GLP-1 drug pending global trial data.
May 28, 2026
NICE updates type 2 diabetes guidance in England, recommending earlier use of SGLT-2 inhibitors and GLP-1 receptor agonists. Separately, a study finds SGLT2 inhibitors improve survival in Takotsubo syndrome patients.
Mar 17, 2026
New NICE guidance recommends offering SGLT-2 inhibitors earlier in type 2 diabetes treatment, potentially preventing 17,000 deaths over three years while saving the NHS £560 million through generic medicines.
Mar 10, 2026
AstraZeneca won a Federal Court injunction blocking Pharmacor from selling generic dapagliflozin products in Australia until a full patent trial. The patent expires October 22, 2027.
Mar 03, 2026
New studies show SGLT2 inhibitors and GLP-1 receptor agonists reduce risks of kidney failure, cardiovascular events, and liver complications in patients with type 2 diabetes, with particularly strong benefits in those with cirrhosis.
Mar 02, 2026
The Federal Court of Australia granted AstraZeneca an interlocutory injunction on 16 February 2026 preventing Pharmacor from launching generic dapagliflozin products pending infringement proceedings, marking the second such injunction in three months.
Feb 13, 2026
Real-world study finds SGLT2 inhibitors reduce chronic kidney disease and acute kidney injury risk more effectively than GLP-1 receptor agonists in patients with type 2 diabetes, with greatest benefits in those without preexisting kidney disease.
